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Summary
Objective: Compare the expression and regulation of nuclear receptors (NRs) in osteoarthritic and normal human articular cartilage.
Method: The transcriptional levels of 48 NRs and additional related proteins were measured in mRNA from human articular cartilage from
subjects with osteoarthritis (OA) and compared to samples from subjects without OA, using microarrays, individual quantitative reverse
transcriptase polymerase chain reaction assays, and a custom human NR TaqMan Low Density Array (TLDA). The functional effect of liver
X receptor (LXR) activity in cartilage was studied by measuring proteoglycan (PG) synthesis and degradation in articular cartilage explant
cultures following treatment with the synthetic LXR agonist T0901317.
Results: Thirty-one of 48 NRs analyzed by TLDA were found to be measurably expressed in human articular cartilage; 23 of these 31 NRs
showed signiﬁcantly altered expression in OA vs unaffected cartilage. Among these, LXRa and LXRb, and their heterodimeric partners retinoid
X receptor (RXR)a and RXRb were all expressed at signiﬁcantly lower levels in OA cartilage, as were LXR target genes ABCG1 and apoli-
poproteins D and E. Addition of LXR agonist to human OA articular chondrocytes and to cartilage explant cultures resulted in activation of
LXR-mediated transcription and signiﬁcant reduction of both basal and interleukin (IL)-1-mediated PG degradation.
Conclusions: Articular cartilage expresses a substantial number of NRs, and a large proportion of the expressed NRs are dysregulated in OA.
In particular, LXR signaling in OA articular cartilage is impaired, and stimulation of LXR transcriptional activity can counteract the catabolic
effects of IL-1. We conclude that LXR agonism may be a possible therapeutic option for OA.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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The nuclear receptor (NR) superfamily consists of a large
group of ligand-inducible or ‘‘orphan’’ transcriptional regula-
tor proteins. To date, 49 members have been identiﬁed in
the human genome1. NRs are a very ‘‘druggable’’ class of
proteins; synthetic ligand analogs have been produced for
nearly all NRs with known natural ligands2. Since NRs mod-
ulate diverse cellular functions associated with various dis-
eases (cancer, osteoporosis, diabetes, etc.), they constitute
an important group of candidate pharmacological
targets3e9.
Osteoarthritis (OA) is a highly prevalent, progressive, de-
bilitating disease characterized by gradual destruction of ar-
ticular cartilage. Chondrocytes constitute the primary cellaPresent address: GlaxoSmithKline, 1250 S Collegeville Road,
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832type in articular cartilage and they are responsible for the syn-
thesis andmaintenance of the cartilagematrix that surrounds
the cells. This matrix provides cartilage with the biophysical
characteristics that are important for the tissue to act as an
effective articulating surface. Chondrocytes maintain proper
homeostasis of cartilage tissue by balancing expression and
response to anabolic and catabolic factors. In OA this bal-
ance appears improperly skewed toward catabolism, result-
ing in gradual loss of cartilage extracellularmatrix. SinceNRs
are important transcriptional regulators within cells, dysregu-
lation of NR expression in OA could provide important clues
into the pathophysiology of the disease as well as provide
possible points of therapeutic intervention.
Despite the recognized importance of NRs in the transcrip-
tional regulation of various cellular pathways, to date only
a few NRs have been suggested to potentially play a role
in OA, including estrogen receptor (ER) alpha (ERa,
NR3A1)10e19, vitamin D receptor (VDR, NR1I1)20e22, peroxi-
some proliferator-activated receptor gamma (PPARg,
NR1C3)23e26, glucocorticoid receptor (GR, NR3C1)27,28, and
the orphan NRs NURR1 (NR4A2)29 and Rev-ErbAa
(NR1D1)30. Here we describe an evaluation of the expression
of 48 human NRs in articular cartilage from OA patients
833Osteoarthritis and Cartilage Vol. 17, No. 7compared to unaffected individuals. These experiments re-
vealed that articular cartilage expressesmanyNRsand several
of thesearedysregulated inosteoarthritic cartilage compared to
normal cartilage, includingmost of thosementioned abovewith
prior associationwithOA.Expression of liver X receptor (LXR)a
(NR1H3) and LXRb (NR1H2) along with LXR heterodimeric
partners retinoid X receptor (RXR)a (NR2B1) and RXRb
(NR2B2) was found to be signiﬁcantly reduced in human OA
cartilage compared to normal. This deﬁcit in LXR and RXR ex-
pression in OA cartilage was accompanied by decreased ex-
pression of LXR-responsive genes. Treatment of human
articular cartilage explants in vitro with an LXR agonist in-
creased LXR target gene expression and reduced cytokine-in-
duced proteoglycan (PG) degradation. We conclude that
correction of an LXR signaling defect in OA cartilage by treat-
ment with an LXR agonist may be a novel disease-modifying
therapeutic option for treatment of OA.Experimental proceduresMEDIA, CHEMICALS AND REAGENTSCell culture reagents were obtained from Gibco-BRL
(Grand Island, NY, USA). Interleukin (IL)-1b, tumor necrosis
factor (TNF)a, and oncostatin M (OSM) were purchased
from R&D Systems (Minneapolis, MN, USA). LXR
agonist T0901317 [N-(2,2,2-triﬂuoro-ethyl)-N-[4-(2,2,2-triﬂu-
oro-1-hydroxy-1-triﬂuoromethyl-ethyl)-phenyl]-benzenesulf-
onamide]31,32 was prepared following standard chemical
syntheses from published literature. Human Universal Ref-
erence Total RNA (catalog #636538) was purchased from
Clontech (Mountain View, CA, USA). Dimethylmethylene
blue (DMMB) was purchased from Polysciences Inc. (War-
rington, PA, USA). Shark and whale chondroitin sulfate was
obtained from Fluka Biochemika (Buchs, Switzerland). Pro-
teinase K was from Roche Molecular Biochemicals
(Indianapolis, IN, USA). Fresh human OA and normal artic-
ular cartilage for cell culture experiments were obtained
from the National Disease Research Interchange (Philadel-
phia, PA, USA).ISOLATION OF RNA FROM PRIMARY CARTILAGE TISSUE AND
FROM CHONDROCYTES IN CULTURERNA was isolated from human osteoarthritic articular carti-
lage samples obtained from patients (n¼ 20, mean
age¼ 66.2 years, range 49e84 years) undergoing total
knee replacement surgery (New England Baptist Hospital,
Boston, MA, USA), or from non-osteoarthritic cartilage ob-
tained from above-knee amputations (n¼ 10, mean
age¼ 71.6 years, range 43e100) (Clinomics, Pittsﬁeld, MA,
USA). The OA cartilage samples were obtained as whole
joints within 2 h of surgery, and the articular cartilage was
shaved from the joint surfaces taking great care to avoid
any pannus, ﬁbrotic tissues, subchondral bone, and other
non-cartilaginous regions of the joint. Non-osteoarthritic
(‘‘normal’’) cartilage samples were obtained from individuals
without a clinical diagnosis or symptoms of OA, and the
specimens were evaluated histologically to conﬁrm the clas-
siﬁcation prior to inclusion in this study. Cartilage pieces
were ﬂash-frozen in liquid nitrogen and stored at 80C until
processed for RNA isolation. RNAwas prepared from the fro-
zen cartilageas describedpreviously33. IsolationofRNA from
chondrocytes inmonolayer culture was performed using TRI-
zol reagent (Invitrogen) according to the manufacturer’s
protocol.CHONDROCYTE CELL CULTUREChondrocytes were isolated from fresh human articular
cartilage using a standard method previously described33.
Cells were cultured in 10% fetal bovine serum (FBS) con-
taining Dulbecco’s modiﬁed Eagle medium (DMEM)/F12
growth media for 2e3 days in 12 well culture plates at a den-
sity of 1e2 10E6 cells/well. Chondrocyte cultures were
stimulated with cytokines (TNFa 10 ng/ml, IL-1b
1 ng/ml) for 18 h or with LXR agonist (T0901317, 2 mM ﬁnal
concentration) for 26 h, in triplicate wells.MEASUREMENT OF mRNA CHANGES IN OSTEOARTHRITIC
AND NORMAL CARTILAGE USING MICROARRAYSGlobal gene expression changes in RNA from osteoar-
thritic cartilage (n¼ 20) as well as from non-osteoarthritic
cartilage (n¼ 10) samples described above were analyzed
using the Human Genome HG-U95Av2 GeneChip Array
(Affymetrix, Santa Clara, CA, USA), as described
previously33.cDNA SYNTHESIS AND QUANTITATIVE REVERSE
TRANSCRIPTASE POLYMERASE CHAIN REACTION (QRT-PCR)cDNA was prepared from puriﬁed RNA using the High-
Capacity cDNA Archive Kit (Applied Biosystems, catalog
#4322171) according to the manufacturer’s instructions.
Quantitative real-time PCR utilized either human TaqMan
Gene Expression Assays or TaqMan Low Density Arrays
(TLDAs) from Applied Biosystems. Thermal cycling was
performed using either an ABI Prism 7900 Sequence De-
tection System (for TLDA) or an ABI Prism 7700 Sequence
Detection System (for TaqMan Gene Expression Assays).
RNA for TaqMan analysis was puriﬁed from dissected and
frozen cartilage tissue as described above, followed by two
more rounds of phenol/chloroform extraction followed by
RNeasy (Qiagen) column puriﬁcation. RNA was treated
with DNase (Qiagen) during RNeasy column puriﬁcation,
and again following the RNA puriﬁcation using DNA-free
(Ambion, Austin, TX, USA), following the manufacturer’s in-
structions. Human Universal RNA (Clontech) was used to
generate standard curves for each assay. Pre-designed
TaqMan probe/primer assay sets (Gene Expression As-
says, Applied Biosystems) for individual qRT-PCR assess-
ments were obtained for the following LXR target genes:
Abca1 (Hs01059122_m1), Abcg1 (Hs00245154_m1),
Apoe (Hs00171168_m1), stearoyl-CoA desaturase (Scd)
(Hs00748952_s1), sterol regulatory element binding tran-
scription factor 1 (Srebf1) (Hs00231674_m1) along with
the endogenous control glucuronidase beta (Gusb)
(4333767F).
A TLDA was custom designed and ordered from Applied
Biosystems, containing Gene Expression Assays capable
of measuring mRNA for: 48 of the 49 known human NRs
(NR2A3/Hnf4b was omitted due to lack of an available as-
say); NR co-repressors (Ncor1 and Ncor2 known LXR tar-
get genes [Abcg1, apolipoproteins D and E (Apod and
Apoe)]; endogenous control normalizer genes (18S rRNA,
B2m, Gapdh, Gusb, Hprt1, Pgk1, Ppia, Rplp0, Tbp, Tfr);
and a gene known to be overexpressed in OA articular car-
tilage (Prss11/Htra1)34,35 as a positive control. The catalog
numbers for these assays are listed in Table I. The assay
primer/probe sets were preloaded in triplicate into each of
the 384 wells in a ‘‘Format 64’’ TLDA. Each port on the
TLDA (four ports total per TLDA) received 100 ml TaqMan
reaction consisting of cDNA corresponding to 75 ng of total
834 L. A. Collins-Racie et al.: NR expression in OA cartilageRNA combined with 1 TaqMan Universal Master Mix.
The comparative CT method of relative quantiﬁcation
36 us-
ing Gusb as normalizer compared to the CT value of the tar-
get gene (DCT) was used. Relative quantiﬁcation (RQ, or
fold-change) between different sample groups (e.g., OA
vs normal) was then determined according to the 2DDCT
method36, where DDCT¼DCT treated sampleDCT con-
trol sample(s). The mean of the expression values for all
of the normal samples (n¼ 10) was used as the calibrator
for these calculations.CARTILAGE PG ANALYSISFresh cartilage explants (w15 pieces, a total of
w165 mg/well) from human OA donors were cultured for
10 days in 1 ml of DMEM/F12 containing 1% Nutridoma
(Roche Applied Science, Indianapolis, IN, USA). During
the 10 days, the explants were incubated with cytokines
(1 ng/ml IL-1bþ 5 ng/ml OSM) with or without LXR agonist
T0901317 (5, 10, 20 mM). Culture medium was replaced
every 2 days with fresh cytokines and LXR agonist. Release
of PGs was measured in these cultures using a DMMB
assay37. Possible cytotoxic effects of cellular treatments
were assessed by measuring lactate levels in culture media
as an indicator of cellular metabolism and viability using
a kit from Trinity Biotech (Berkeley Heights, NJ, USA).
Explants were then digested with proteinase K and assayed
for total PG content.STATISTICAL ANALYSISData are expressed as mean standard error of the
mean (S.E.M.). Statistical signiﬁcance was determined by
two-tailed Welch t test using either Expressionist Software
(Genedata, Basel, Switzerland) or Microsoft Excel 2000;
for either test, P< 0.05 was set as the signiﬁcance
threshold.ResultsEXPRESSION AND DYSREGULATION OF NRs IN HUMAN OA
ARTICULAR CARTILAGEA focused analysis to identify the spectrum of expres-
sion of nuclear hormone receptors in global gene expres-
sion data from OA vs normal articular cartilage33 was
undertaken. The mean transcript levels of NRs repre-
sented on the gene chips and judged present in cartilage
are listed in Table I. Although relatively few NRs were ex-
pressed in cartilage at levels measurable on the gene
chips, these data support a previous report30 that Rev-Er-
bAa (NR1D1) is one of the most abundant NRs in articular
cartilage. In addition, LXRb and RXRa were also found to
be relatively highly expressed in articular cartilage, raising
interest in a possible role for LXR signaling in cartilage.
Preliminary qRT-PCR performed on cartilage RNA from
a small subset of the donors proﬁled by gene chip con-
ﬁrmed LXRa, LXRb, and RXRa expression, and sug-
gested that these NRs may be downregulated in OA
cartilage (data not shown).EVALUATION OF NR REGULATION IN OA CARTILAGE USING
A CUSTOM TLDAThe preliminary analysis of NR expression provided
impetus to expand the study beyond the use of gene chips(limited by sensitivity) and individual qRT-PCR assays (lim-
ited by the amount of cartilage RNA from OA and normal
human donors) to a methodology that would allow compre-
hensive measurement of all human NRs with limited
amounts of RNA and with high sensitivity and precision.
To accomplish this, a custom human NR TLDA (hNR-
TLDA) was created containing assays for 48 of the 49
known human NRs (Table I; no assay was available for
NR2A3/HNF4b), two NR co-repressors (NCOR1 and
NCOR2), 10 endogenous control ‘‘normalizer’’ genes,
and a gene (PRSS11) known to be robustly expressed
and upregulated in OA cartilage from the gene chip data
[Fig. 1(A)]. In addition, assays were included to measure
expression of three known LXR target genes (ABCG1,
APOD, and APOE)38e41 to determine whether the putative
downregulation of LXR expression in OA cartilage would
be reﬂected in the expression of genes directly regulated
by LXR. All of the NR assays were capable of detecting
expression in ampliﬁcation reactions containing 75 ng of
universal RNA with CT values< 34, with the exception of
the photoreceptor-speciﬁc nuclear receptor (PNR) assay
(presumably due to under-representation of the highly tis-
sue-speciﬁc PNR in the universal RNA42). The design of
the hNR-TLDA incorporated triplicate assays for each
gene. Intra- and inter-assay reproducibility was also tested
using the universal RNA control and found to be acceptable
when CT values were less than 34 (data not shown).
RNA from normal (n¼ 10) and OA cartilage (n¼ 20) sam-
ples was assayed using this hNR-TLDA (75 ng RNA per
port). The choice of GUSB as the endogenous control nor-
malizer gene was based upon a post hoc analysis of vari-
ability in the expression of the 10 endogenous control
genes across all cartilage samples and because its expres-
sion level (CT value) was similar to most of the NRs under
study (Table I).
PRSS11 and APOD were the only two genes repre-
sented on the TLDA that were expressed highly enough
in both OA and normal cartilage to test the concordance
of hNR-TLDA data to microarray data in our sample set.
Average expression of PRSS11 in each cohort measured
by either the HG-U95Av2 GeneChip [Fig. 1(A)] or the
hNR-TLDA [Fig. 1(B)] provided very similar results that
conﬁrm upregulation of this gene in OA articular carti-
lage34,35. For APOD, the microarray data [Fig. 1(C)] and
the TaqMan data [Fig. 1(D)] both indicated a signiﬁcant re-
duction in APOD expression in OA cartilage. However, the
fold-differences in APOD gene expression between OA
and normal cartilage did not closely agree between the
two technologies, presumably because the average ex-
pression value for APOD in OA cartilage by microarray
was at the lower limit of reliable detection [w10 parts per
million (ppm)] while TaqMan expression values for
APOD in OA cartilage were well within the range of quan-
titation (average CTw 25).
Thirty-one of the 48 NRs assayed were found to be mea-
surably expressed by human articular cartilage using the
hNR-TLDA (Table I). Genes for which the particular assays
did not reach a CT value< 34 when data from all subjects
(OA and normal) were averaged were considered not to be
reliably expressed and were excluded from further analysis.
In addition, data from the assay for NR1I1 (VDR) were highly
variable between subjects and were also excluded. The
mean expression values for all normal articular cartilage
samples were used as the calibrator and GUSB was used
as the normalizer for this analysis. A list of the NRs and their
expression values in normal articular cartilage (expressed as
average CT) are shown in Table I. Of the 31 NRs reliably
Table I
Gene Expression Assay content and cartilage expression data for genes on Affymetrix GeneChips and the human custom NR-TLDA
Gene symbol Gene name Alias GeneChip average
signal (ppm)
TaqMan
assay
TaqMan
average CT
Welch t test
NRs OA vs normal
NR0B1 NR subfamily 0, group B,
member 1
DAX1 ND Hs00230864_m1 37.56* No value
NR0B2 NR subfamily 0, group B,
member 2
SHP1 ND Hs00222677_m1 40.00* No value
NR1A1 Thyroid hormone receptor,
alpha
TRa ND Hs00268470_m1 26.99 0.012
NR1A2 Thyroid hormone receptor,
beta
TRb ND Hs00230861_m1 27.25 0.529
NR1B1 Retinoic acid receptor, alpha RARa ND Hs00230907_m1 27.22 1.2EL 07
NR1B2 Retinoic acid receptor, beta RARb ND Hs00233407_m1 28.05 0.019
NR1B3 Retinoic acid receptor, gamma RARg ND Hs00171273_m1 26.85 0.049
NR1C1 Peroxisome proliferator-activated
receptor alpha
PPARa ND Hs00231882_m1 28.97 0.033
NR1C2 Peroxisome proliferator-activated
receptor delta
PPARd ND Hs00606407_m1 28.32 2.2EL 06
NR1C3 Peroxisome proliferator-activated
receptor gamma
PPARg ND Hs00234592_m1 31.24 0.003
NR1D1 NR subfamily 1, group D,
member 1
Rev-Erba 20.6 Hs00253876_m1 24.27 0.010
NR1D2 NR subfamily 1, group D,
member 2
Rev-Erbb ND Hs00233309_m1 27.25 0.137
NR1F1 RAR-related orphan receptor A RORa ND Hs00536545_m1 27.64 0.288
NR1F2 RAR-related orphan receptor B RORb ND Hs00199445_m1 33.27* No value
NR1F3 RAR-related orphan receptor C RORg ND Hs00172860_m1 28.45 0.308
NR1H2 NR subfamily 1, group H,
member 2
LXRb 9.3 Hs00173195_m1 28.37 0.001
NR1H3 NR subfamily 1, group H,
member 3
LXRa ND Hs00172885_m1 29.40 0.032
NR1H4 NR subfamily 1, group H,
member 4
FXR ND Hs00231968_m1 39.50* No value
NR1I1 Vitamin D (1,25-dihydroxyvitamin
D3) receptor
VDR ND Hs00172113_m1 32.42y No value
NR1I2 NR subfamily 1, group I,
member 2
PXR ND Hs00243666_m1 31.95 0.010
NR1I3 NR subfamily 1, group I,
member 3
CAR ND Hs00231959_m1 37.21* No value
NR2A1 Hepatocyte nuclear factor 4,
alpha
HNF4A ND Hs00230853_m1 35.17* No value
NR2A2 Hepatocyte nuclear factor 4,
gamma
HNF4G ND Hs01071345_m1 34.86* No value
NR2B1 Retinoid X receptor, alpha RXRa 24.3 Hs00172565_m1 26.37 4.7EL 04
NR2B2 Retinoid X receptor, beta RXRb ND Hs00232774_m1 25.90 0.008
NR2B3 Retinoid X receptor, gamma RXRg ND Hs00199455_m1 35.19* No value
NR2C1 NR subfamily 2, group C,
member 1
TR2 ND Hs00172676_m1 28.37 4.9EL 04
NR2C2 NR subfamily 2, group C,
member 2
TR4 ND Hs00231489_m1 28.17 0.004
NR2E1 NR subfamily 2, group E,
member 1
TLX ND Hs00172664_m1 40.00* No value
NR2E3 NR subfamily 2, group E,
member 3
PNR ND Hs00183917_m1 38.69* No value
NR2F1 NR subfamily 2, group F,
member 1
COUP-TF1 ND Hs00818842_m1 32.10 0.082
NR2F2 NR subfamily 2, group F,
member 2
COUP-TF2 ND Hs00819630_m1 29.23 0.002
NR2F6 NR subfamily 2, group F,
member 6
EAR2 ND Hs00172870_m1 26.95 0.036
NR3A1 ER 1 ERa ND Hs00174860_m1 27.52 0.030
NR3A2 ER 2 ERb ND Hs00230957_m1 33.17* No value
NR3B1 Estrogen-related receptor
alpha
ERRa ND Hs00607062_gH 27.96 0.008
NR3B2 Estrogen-related receptor
beta
ERRb ND Hs00374442_m1 39.28* No value
NR3B3 Estrogen-related receptor
gamma
ERRg ND Hs00155006_m1 38.99* No value
NR3C1 Glucocorticoid receptor GR 8.4 Hs00230818_m1 25.22 0.002
(continued on next page)
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Table I (continued )
Gene symbol Gene name Alias GeneChip average
signal (ppm)
TaqMan
assay
TaqMan
average CT
Welch t test
NRs OA vs normal
NR3C2 NR subfamily 3, group C,
member 2
MR ND Hs00230906_m1 30.45 0.022
NR3C3 Progesterone receptor PR ND Hs00172183_m1 32.18 0.001
NR3C4 Androgen receptor AR ND Hs00171172_m1 28.21 0.034
NR4A1 NR subfamily 4, group A,
member 1
NUR77 ND Hs00374225_m1 28.99 0.335
NR4A2 NR subfamily 4, group A,
member 2
NURR1 ND Hs00428691_m1 29.68 0.656
NR4A3 NR subfamily 4, group A,
member 3
NOR1 ND Hs00175077_m1 31.37 4.8EL 04
NR5A1 NR subfamily 5, group A,
member 1
SF1 ND Hs00610436_m1 40.00* No value
NR5A2 NR subfamily 5, group A,
member 2
LRH-1 ND Hs00187067_m1 31.22* No value
NR6A1 NR subfamily 6, group A,
member 1
GCNF ND Hs00364256_m1 33.29* No value
Endogenous controls
GUSB Glucuronidase beta 15.10 Hs99999908_m1 27.14 0.863
TFRC Transferrin receptor (p90) CD71 6.40 Hs99999911_m1 27.62 0.863
LXR targets
ABCG1 ATP-binding cassette, sub-family G
(WHITE), member 1
ND Hs00245154_m1 30.82 5.9EL 05
APOD Apolipoprotein D 106 Hs00155794_m1 21.09 8.9EL 05
APOE Apolipoprotein E ND Hs00171168_m1 26.72 2.4EL 04
Positive control
PRSS11 HTRA serine peptidase 1 HTRA 100.8 Hs00170197_m1 22.46 0.002
Co-repressors
NCOR1 NR co-repressor 1 13.2 Hs00196920_m1 26.38 4.7EL 05
NCOR2 NR co-repressor 2 SMRT 18 Hs00196955_m1 25.73 2.0EL 06
A listing of the genes represented by assays on the hNR-TLDA included 48 of the 49 known human NRs (all except NR2A3), two NR co-
regulators, a positive control representing a transcript previously shown to be well-expressed in cartilage and upregulated in OA cartilage,
three known LXR target genes, and 10 endogenous control ‘‘normalizer’’ genes. All assays tiled on the custom hNR-TLDA are listed in alpha-
betical order, grouped by function, with columns representing the Gene Expression Assay (Applied Biosystems) number, average signal value
(in ppm) for that particular gene within all normal samples on GeneChip, average CT values for each assay across all normal samples, and the
P values for the comparison of the TLDA results for the OA vs normal comparisons.
*Eliminated from further analysis because combined average CT> 34 across normal and OA cohorts.
yEliminated from further analysis because of erratic assay performance.
836 L. A. Collins-Racie et al.: NR expression in OA cartilageexpressed in articular cartilage, 23 were expressed at signif-
icantly different levels (P< 0.05 by Welch t test) in OA artic-
ular cartilage compared to normal (Table I). The differences
in expression of each NR in all OA cartilage samples com-
pared to normal, expressed as fold-change, are shown in
Fig. 2. In addition to the 48 NRs, the transcript levels for
co-repressors NCOR1 and NCOR2 were also assayed in
all cartilage samples. Compared to normal cartilage,
NCOR1 expression was decreased 1.6-fold (P¼ 4.4Ee 5)
in OA cartilage and NCOR2 expression was 2.3-fold lower
in OA cartilage (P¼ 2.0Ee 6).EVALUATION OF LXR TARGET GENE EXPRESSION IN HUMAN
OA CARTILAGE COMPARED TO UNAFFECTED CARTILAGELXRs and associated co-receptors were among the 23
NRs dysregulated in OA cartilage, conﬁrming earlier pre-
liminary data. LXRa (NR1H3), LXRb (NR1H2), RXRa
(NR2B1) and RXRb (NR2B2) were all found to be ex-
pressed at signiﬁcantly lower levels in OA cartilage com-
pared to normal (Fig. 2). Analysis of qRT-PCR data was
performed to determine whether decreased expression
of LXRs and RXRs resulted in signiﬁcant reduction in ex-
pression of LXR target genes in these same OA andnormal cartilage samples. As shown in Fig. 3, ABCG1,
APOD, and APOE all showed signiﬁcantly decreased ex-
pression in OA cartilage compared to normal, reﬂecting
a deﬁcit in LXR activity in OA cartilage.OACHONDROCYTES INDUCE LXR TARGETGENESFOLLOWING
TREATMENT WITH A SYNTHETIC LXR AGONISTGiven reduced LXR and RXR expression in OA chon-
drocytes, experiments were performed to determine
whether these cells were responsive to a synthetic LXR
agonist. Primary articular chondrocytes isolated from hu-
man OA donors (n¼ 3) were grown in monolayer cultures
with the LXR agonist T0901317 (2 mM) or vehicle in trip-
licate cultures per treatment. Following 16 h of incubation,
the effect of T0901317 on the expression of LXR target
genes was assayed by qRT-PCR. As shown in Fig. 4, ex-
pression of ABCA1 and ABCG1 as well as LXRa, APOE,
SREBF1, and SCD, were all signiﬁcantly increased in
LXR agonist-treated cultures compared to vehicle con-
trols; the ABC cassette genes ABCA1 and ABCG1
showed the most dramatic induction by T0901317 treat-
ment of all of the genes studied (>20- and 80-fold,
respectively).
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Fig. 1. Comparison of qRT-PCR TLDA assay data to GeneChip probe set data. Two genes represented by assays on the TLDA were ex-
pressed highly enough in both normal and OA cartilage to allow measurement and comparison of expression differences on gene chips
and TLDA. Expression differences between OA and normal cartilage were determined for PRSS11 (A) and APOD (C) on gene chips, and
compared to TLDA data for PRSS11 (B) and APOD (D). Bars represent the average expression of PRSS11 or APOD in normal cartilage
(n¼ 10; light gray bars) or OA cartilage samples (n¼ 20, average of 10 non-lesional OA and 10 lesional OA cartilage; black bars) measured
either by Affymetrix U95Av2 gene chips (expressed in transcript ppm) or by the custom hNR-TLDA (expressed in average fold-change per
cohort, using GUSB as normalizer and the mean of all normal cartilage samples as the calibrator). Values represent the mean S.E.M. for
each group. **P< 0.01 by Welch t test.
0.1
1
10 Normal Cartilage
OA  Cartilage
A
v
e
r
a
g
e
 
F
o
l
d
 
C
h
a
n
g
e
 
v
s
.
 
A
l
l
 
N
o
r
m
a
l
s
 
TR
α
*
TR
β
R
AR
α
*
*
R
AR
β*
R
AR
γ*
PP
AR
α
*
PP
AR
δ*
*
PP
AR
γ*
* R
ev
-E
rb
α
*
* R
ev
-E
rb
β
R
O
Rα
R
O
Rγ
LX
R
β**
LX
R
α
*
PX
R
**
R
XR
α
*
*
R
XR
β**
TR
2*
*
TR
4*
*
CO
UP
-T
F1
CO
UP
-T
F2
**
EA
R
2*
ER
α
*
ER
R
α
*
*
G
R*
*
M
R
*
PR
**
AR
*
N
UR
77
N
UR
R1
N
O
R1
**
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Fig. 3. Target genes for LXR are expressed at signiﬁcantly lower
levels in osteoarthritic articular cartilage compared to normals.
Comparison of the average fold-change (RQ) for LXR target genes
ABCG1, APOD and APOE measured on the hNR-TLDA. Expres-
sion values (CT) for each sample were normalized to the average
expression (CT average) for all endogenous controls, and com-
pared to all normal samples. Bars represent the mean RQ S.E.M.
for each cohort (normal, n¼ 10; OA, n¼ 20). **P< 0.01 by Welch t
test.
838 L. A. Collins-Racie et al.: NR expression in OA cartilageTRANSCRIPTIONAL REGULATION OF LXR AND RXR BY
INFLAMMATORY CYTOKINESThe reduction in LXR and RXR expression in OA chon-
drocytes suggested that they might be under the transcrip-
tional control of signaling pathways that are altered in OA. It
is well established that IL-1 and TNF are important media-
tors of OA43e47, so experiments were performed to deter-
mine whether these cytokines can regulate LXR and RXR
expression in articular chondrocytes. Primary articular
chondrocytes were isolated from human donors (n¼ 7;
n¼ 4 normal, n¼ 3 OA) and grown in monolayer cultures
with IL-1b, TNFa, or vehicle, and the expression of LXR
and RXR isoforms was measured by qRT-PCR. These
experiments showed that RXRa expression was signiﬁ-
cantly reduced by both IL-1 and TNF treatment in articular
chondrocytes from both normal and OA donors [Fig. 5(C)].
Interestingly, LXRa expression was signiﬁcantly reduced
by both IL-1 and TNF treatment only in chondrocytes from
normal donors [Fig. 5(A)]. A trend toward reduced LXRa
expression was also seen in IL-1 and TNF-treatedFig. 4. Primary chondrocytes from human OA articular cartilage respond
Articular chondrocytes isolated from late-stage OA knee cartilage from h
with or without LXR agonist T0901317 (2 mM) in triplicate cultures per trea
was assayed by qRT-PCR to measure the effect of T0901317 on the expre
as the average fold-change for each gene in treated cultures compared
ABCG1. Panel B, NR1H3 (LXRa), APOE, Schondrocytes from OA donors, but the effect did not reach
signiﬁcance in this sample set. In contrast, LXRb expres-
sion was largely unchanged by cytokine treatment of pri-
mary chondrocytes [Fig. 5(B)]; only IL-1 treatment of
normal chondrocytes showed a small but signiﬁcant reduc-
tion in LXRb expression. RXRb showed an expression pat-
tern similar to LXRb whereby signiﬁcant downregulation
was seen only for IL-1 treated normal chondrocytes
[Fig. 5(D)]. RXRg was expressed at levels too low for quan-
titative assessment of gene regulation by cytokine treat-
ment (data not shown).LXR AGONIST TREATMENT MITIGATES CYTOKINE-INDUCED
PG DEGRADATION IN HUMAN OA ARTICULAR CARTILAGEExperiments were performed to evaluate the effect of
LXR agonist treatment of human articular cartilage explants
on PG synthesis and degradation following treatment with
catabolic cytokines. Figure 6 shows the results from a repre-
sentative experiment in which cartilage explants from
human OA cartilage were treated with or without IL-1b/
OSM to stimulate PG degradation following addition of in-
creasing doses of the LXR agonist compound T0901317.
After 10 days in culture, the highest dose of T0901317
(20 mM) signiﬁcantly decreased endogenous PG release
(no cytokine treatment) from the OA cartilage explants
into the conditioned medium [20 mM T0901317 vs dimethyl
sulfoxide (DMSO) control], and this activity was also
reﬂected in signiﬁcantly increased retention of PG in the
explants [20 mM T0901317 vs DMSO control]. Addition of
IL-1b/OSM to the explant cultures resulted in a signiﬁcant
and substantial increase in PG release from the explants
and a concomitant decrease in PG remaining in the
explants, while co-treatment with 10 mM or 20 mM
T0901317 resulted in a signiﬁcant reduction in cytokine-
mediated PG release to the conditioned media and in-
creased PG retention in the explants.Discussion
An analysis of microarray data on human cartilage sam-
ples from OA patients and unaffected controls33 for NR ex-
pression and regulation in OA cartilage suggested
dysregulation of some NRs in OA, but the inherently low
levels of NR expression limited the analysis because most
NRs were below the microarray lower limit of quantitation.to LXR agonist treatment by upregulating known LXR target genes.
uman donors (n¼ 3) were grown in monolayer culture and treated
tment group for 26 h. RNA prepared from the cells following culture
ssion of LXR target genes in OA chondrocytes. Data are presented
to untreated, S.E.M. Panel A, ABC cassette genes ABCA1 and
REBF1, SCD. *P< 0.05, **P< 0.01.
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839Osteoarthritis and Cartilage Vol. 17, No. 7Since NR dysregulation in OA was largely unknown, the im-
portant implications of these data with regard to increasing
understanding of gene regulation in OA and discovering
novel drug targets led us to consider utilizing a recently-de-
veloped, moderate-throughput technology e TLDAs e to
monitor all human NRs in OA vs normal cartilage. This ap-
proach allowed simultaneous measurement of all NR tran-
scripts with much greater sensitivity than the microarrays,
which was necessary to measure the relatively low-level
transcription of many of the NRs. Moreover, the TLDA plat-
form uses far less RNA than ‘‘traditional’’ TaqMan individ-
ual assays for the number of genes studied here, which was
an important consideration since the OA and normal carti-
lage RNA samples were precious and ﬁnite.
We found that almost two-thirds of all known NRs were
expressed in human articular cartilage. These ﬁndings
were consistent with a previous study by Chaturvedi
et al.30 who found evidence for expression of about 30
NRs in human OA cartilage and particularly abundant
expression of Rev-Erba, but no comparison of NR expres-
sion in OA vs normal cartilage was reported. In the present
study, a surprisingly high proportion (approximately 75%) of
expressed NRs showed altered expression in OAcompared to normal cartilage. Although this seems inordi-
nately high, this is one of the ﬁrst reported in-depth studies
of global NR regulation in a disease tissue and future inves-
tigations on affected tissues from other disease states will
determine whether or not our ﬁndings in OA cartilage are
unusual. The changes in NR expression that we observed
in OA cartilage are consistent with most previous reports
linking alterations in activity or expression of some NRs
with OA. For instance, an association of ER and OA has
been found by haplotype analyses18,19, and reduced estro-
gen signaling has been postulated to contribute to an in-
creased incidence of OA in post-menopausal women.
There is evidence that estrogen replacement therapy may
provide a protective effect in OA48, and 17-b-estradiol has
been shown to suppress matrix metalloproteinase (MMP)
expression in synovial cells49 and in chondrocytes50. Con-
sistent with these ﬁndings, we found that ERa expression
in human OA cartilage is almost 10-fold lower than normal.
Similarly, reduced expression of GR27 and PPARg51 in OA
cartilage has been previously reported, consistent with our
observations, and the use of agonists to these NRs has
been shown to diminish some catabolic activities in disease
tissue25,51.
Fig. 6. LXR agonist treatment of human OA cartilage explants mitigates cytokine-induced PG degradation. Fresh human OA cartilage explants
were cultured for 10 days with 1 ng/ml IL-1b plus 5 ng/ml OSM with or without LXR agonist T0901317 (5, 10, 20 mM). Percent of total PGs
released into the culture medium S.E.M. (A) and the percent of total PGs retained in the explants S.E.M. (B) are shown. #P< 0.05,
##P< 0.01 in comparison to DMSO control; *P< 0.05, **P< 0.01 in comparison to DMSOþ IL-1/OSM control. Cartilage explants from six
human donors were evaluated in six separate experiments of the same design. The results of a representative experiment on one of the donor
samples are shown.
840 L. A. Collins-Racie et al.: NR expression in OA cartilageOur ﬁndings of dysregulation of several other NRs in OA
cartilage have not been reported previously. In particular,
our ﬁnding that LXRa, LXRb, RXRa, and RXRb are
expressed at signiﬁcantly lower levels in OA cartilage sug-
gested a potential LXR signaling defect in OA, which was
substantiated by signiﬁcantly decreased expression of
genes in OA cartilage known to be directly regulated by
LXR. Previous literature describing the expression or func-
tion of LXR and/or RXR in cartilage is sparse. LXR and RXR
expression was reported in chicken hypertrophic chondro-
cytes52 and responded to synthetic LXR agonists by
increasing LXR target genes involved in cholesterol efﬂux.
Treatment of bovine chondrocytes with hyaluronan hexa-
saccharides was shown to increase expression of retinoic
acid receptor (RAR) and RXR53. The impact of changes
in RXR expression is difﬁcult to predict since RXR can exist
as a homodimer, or can heterodimerize with several other
NRs besides LXRs (reviewed in Ref. 54). RXR biology is
further complicated by the fact that some heterodimeric
receptor complexes (e.g., LXRs, farnesoid X receptor
(FXR), and PPARs) can be independently activated by
either the RXR’s ligand, the RXR partner’s ligand, or by
both; alternatively, other RXR heterodimeric receptor com-
plexes require the partner’s ligand for activation (e.g.,
VDR and thyroid hormone receptor (TR))54. Burrage
et al.55 reported suppression of IL-1b-mediated induction
of MMP-1 and MMP-13 expression in the SW1353 human
chondrosarcoma cell line by treatment with the RXR-spe-
ciﬁc agonist LG100268. In contrast, Castrillo et al.56 re-
ported that LXR agonist treatment of murine macrophagesdid not suppress IL-1b-mediated MMP-13 expression. We
ﬁnd that LXR agonist treatment of human cartilage explants
does not suppress IL-1b-mediated MMP-1 or MMP-13 ex-
pression (Li et al., submitted), suggesting that either the
RXR agonist effect on MMP expression is not mediated
through an LXR/RXR heterodimer or that SW1353 cells
are not accurately reﬂecting the response of primary human
cartilage. Studies comparing LXR and RXR agonists on
gene expression and matrix degradation in explant cultures
should address this question.
A protective role for LXR signaling in OA cartilage is sug-
gested by the ability of a synthetic LXR agonist to block the
cytokine-mediated degradation of PG in human cartilage
explants. The anti-inﬂammatory potential of LXR activation
has been documented previously in other cell types, includ-
ing macrophage57 where LXR agonist treatment sup-
pressed nuclear factor (NF)-kB signaling elicited by
exposure to lipopolysaccharide (LPS) and inhibited numer-
ous inﬂammatory downstream targets of NF-kB such as IL-
6, cyclo-oxygenase-2 (COX-2) and inducible nitric oxide
synthase (iNOS). These inﬂammatory mediators are known
to regulate enzymes responsible for cartilage matrix de-
struction56,58. Since chondrocytes and macrophages are
similar in their production of, and response to, inﬂammatory
cytokines59, it is possible that the mechanism of LXR anti-
inﬂammatory effects in chondrocytes and macrophage
may also be similar. In chondrocytes, we ﬁnd that IL-1b
and TNFa treatment results in signiﬁcantly decreased
expression of LXRs and RXRs, especially the alpha iso-
forms. This may accentuate the catabolic effects of NF-kB
841Osteoarthritis and Cartilage Vol. 17, No. 7stimulation by reducing an important negative feedback.
Studies to further elucidate the mechanism(s) of LXR sup-
pression of cytokine-induced cartilage matrix degradation
in OA are currently in progress.Conﬂict of interest
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